Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01914692|
Recruitment Status : Completed
First Posted : August 2, 2013
Last Update Posted : August 2, 2013
|Condition or disease||Intervention/treatment||Phase|
|Gastric Cancer After D2 Lymph Node Dissection||Drug: Somatostatin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection —a Prospective Randomized Controlled Study|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
Experimental: Somatostatin group
Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.
Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
Placebo Comparator: Blank group
Use the normal saline instead of somatostatin.
- fistula of pancreas [ Time Frame: one year ]number of patients
- amount of bleeding [ Time Frame: six months ]amount of bleeding after the operation
- seroperitoneum [ Time Frame: six months ]seroperitoneum volum of patients
- infection of incisional wound [ Time Frame: one year ]number of patients
- postoperative pancreatitis [ Time Frame: one year ]number of patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01914692
|Study Chair:||Song Wu, Doctor||First Affiliated Hospital of Sun Yat-sen University|